2023 was a big year for CRISPR-based gene editing but challenges remain

2023 was an important year for patients with sickle cell disease. The FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease marking it as the first genetically edited therapy to reach the general market.

Related Keywords

China ,New York ,United States ,United Kingdom ,New York University ,Katie Hasson ,Nicole Verdun ,Peter Marks ,Neville Sanjana ,David Altshuler ,Innovative Genomics Institute ,University College London ,Office Of Therapeutic Products ,York Genome Center ,Affordability Task ,Broad Institute ,Department Of Biology At New York University ,Therapeutic Products ,Biologics Evaluation ,New York Genome Center ,Weill Cornell Medicine ,